Humana stock posts 26.2 percent Q2 revenue growth as estimates reset

Published on 10/04/2026 at 18:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Humana stock closed at USD 388.36 on October 2, 2026, 9.45 percent below its 52-week high. Q2 EPS beat consensus by USD 0.34, while Barclays set a USD 515 target.

CGI-Rendering eines modernen Industriecampus mit Glasfassade und Grünanlage bei blauem Himmel — Honeywell US4448591028 Architektur-Render moderner Industriecampus mit Glas-Stahl-Bürogebäude gepflegten Grünanlagen und blauem Himmel, Illustration mit AI erstellt.

Humana stock (ISIN US4448591028) closed at USD 388.36 on the NYSE on October 2, 2026, up 2.29 percent for the session. The insurer's Q2 2026 results showed revenue of USD 40.89 billion, up 26.2 percent year over year, while adjusted earnings per share reached USD 7.61, according to MarketBeat on October 2, 2026.

Q2 revenue reached USD 40.89 billion

The Q2 revenue figure exceeded the USD 40.58 billion consensus by USD 0.31 billion, while EPS surpassed the USD 7.27 estimate by USD 0.34. The result also compared with adjusted EPS of USD 6.27 in the same period of the prior year, a year-over-year increase of USD 1.34, as MarketBeat reported.

For investors, the combination matters because the top line expanded faster than the prior-year comparison while the earnings figure also cleared expectations. Humana's latest quarter therefore supplies a quantified operating base for the next debate over medical costs and Medicare Advantage membership.

Analysts keep the target range wide

Zacks Research retained a Hold rating after lowering its Q3 2028 EPS estimate to USD 6.58 from USD 6.73, according to MarketBeat on October 2, 2026. The same report listed 15 Buy ratings, 14 Hold ratings and one Sell rating, producing an average target of USD 408.61.

Barclays took the more bullish position on September 25, raising its rating from Equal Weight to Overweight and lifting its price target from USD 407 to USD 515, as reported by Business Insider. The USD 515 target lies 32.6 percent above the October 2 closing price, leaving a sharp gap between the single-house view and the wider consensus.

Medicare membership sets the next test

Humana's investor-relations calendar lists its 3Q 2026 earnings conference call for November 6, 2026, as shown on Humana. The date falls during Medicare Advantage open enrollment, making membership changes, plan pricing and medical-cost trends central metrics for the next report.

A Yahoo Finance report dated October 1, 2026, said Humana expects 600,000 Medicare Advantage members to lose their plans in 2027 and expects to recapture more than 40 percent of those members in other plans, according to Yahoo Finance. That retention question connects the strong Q2 revenue comparison with the pressure facing the next earnings cycle.

Humana stock stays below its yearly high

At USD 388.36, Humana stock stood 9.45 percent below its 52-week high of USD 428.88 and USD 225.25 above its 52-week low of USD 163.11 on October 2, 2026. Market capitalization was USD 46.6 billion and volume was 757,751 shares, keeping the stock's valuation debate tied to both the Q2 beat and the coming membership update.